Home LiteratureArticle Details
PMID: 7705708 Published · ppublish English Comparative Study Journal Article

Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1.

Gynecologic oncology ·Vol. 57 ·No. 1 ·1995-04-00 ·Pages 96-104

Beck T, Weller EE, Weikel W, Brumm C, Wilkens C, Knapstein PG

Abstract

Mutations of the p53 gene often result in the overexpression of p53 protein. Previous studies have suggested that the function of p53 and its mutant protein forms may be linked with the disease course of patients with a breast carcinoma. In the present study, we tested 462 primary breast carcinomas for the presence of p53 antigen using immunohistochemical methods employing antibodies against the clone, DO-1. These tumors were also immunohistochemically stained using the monoclonal antibody, MIB-1, in order to demonstrate the presence of Ki67. Comparison of the presence of p53 with other prognostic parameters revealed highly significant negative correlations with estrogen- and progesterone-receptor status (P < 0.001 and P = 0.001, respectively) as well as positive correlations with both the presence of MIB-1 (P < 0.001) and the histological grading (P = 0.008). The presence of p53 was not correlated with tumor stage and node status. Evaluation of the findings for all 462 tumors as well as for node-positive and -negative subgroups revealed less favorable findings for overall survival and the disease-free period for both p53-positive tumors (for total group, overall survival, P = 0.0002, disease-free period, P = 0.02; for node-positive group, overall survival, P = 0.0004, disease-free period, P = 0.1045) and breast carcinomas with higher proportions of cell nuclei positive for MIB-1 (total, overall survival, P = 0.0026, disease-free period, P = 0.0022; node-positive, overall survival, P = 0.021, disease-free period, P = 0.0882). We were able to demonstrate that p53 expression in breast carcinomas means a significantly worse prognosis for grade II tumors (overall survival, P = 0.0002; disease-free period, P = 0.0116), for overall survival in the case of estrogen-receptor-positive tumors (P = 0.014), and for tumors showing increased proliferation activity (overall survival, P = 0.0477).

MeSH Terms
Antibodies, Monoclonal/analysis Biomarkers, Tumor/analysis Breast Neoplasms/chemistry,mortality,pathology Cell Division Cell Nucleus/chemistry,immunology Disease-Free Survival Female Humans Immunohistochemistry Mutation Prognosis Regression Analysis Survival Analysis Tumor Suppressor Protein p53/analysis,genetics
Chemicals
Antibodies, Monoclonal Biomarkers, Tumor Tumor Suppressor Protein p53
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Beck T
Gynecological Clinic, University of Mainz, Germany.
Weller E E
Weikel W
Brumm C
Wilkens C
Knapstein P G
Article Info
Journal
Gynecologic oncology
Abbr.
Gynecol Oncol
ISSN
0090-8258
Published
1995-04-00
Pages
96-104
Language
English
Region
United States
NLM ID
0365304
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com